Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Boehringer Ingelheim
Moodys
Johnson and Johnson
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Collagenase clostridium histolyticum

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Collagenase clostridium histolyticum: Patents, clinical trial progress, indications

Collagenase clostridium histolyticum is an investigational drug.

There have been 16 clinical trials for Collagenase clostridium histolyticum. The most recent clinical trial was a Phase 3 trial, which was initiated on March 20th 2018.

The most common disease conditions in clinical trials are Dupuytren Contracture, Contracture, and Lipoma. The leading clinical trial sponsors are Advance Biofactures Corporation, Endo Pharmaceuticals, and Tampere University Hospital.

There are seven US patents protecting this investigational drug and one hundred and ninety-three international patents.

Recent Clinical Trials for Collagenase clostridium histolyticum
TitleSponsorPhase
Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal StricturesUniversity Hospital, GhentEarly Phase 1
Xiaflex® Plus Testosterone Treatment Pilot Study ProtocolMen's Health BostonPhase 4
Injection Techniques of EN3835 for the Treatment of EFP (Commonly Known as Cellulite)Endo PharmaceuticalsPhase 2

See all Collagenase clostridium histolyticum clinical trials

Clinical Trial Summary for Collagenase clostridium histolyticum

Top disease conditions for Collagenase clostridium histolyticum
Top clinical trial sponsors for Collagenase clostridium histolyticum

See all Collagenase clostridium histolyticum clinical trials

US Patents for Collagenase clostridium histolyticum

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Collagenase clostridium histolyticum   Start Trial Treatment method and product for uterine fibroids using purified collagenase BioSpecifics Technologies Corporation (Lynbrook, NY) Duke University (Durham, NC)   Start Trial
Collagenase clostridium histolyticum   Start Trial Postpartum cells isolated from umbilical cord tissue, and methods of making and using the same Ethicon, Incorporated (Somerville, NJ)   Start Trial
Collagenase clostridium histolyticum   Start Trial Skincare methods Asan Laboratories Company (Cayman) Limited (Taipei, TW)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Collagenase clostridium histolyticum

Drugname Country Document Number Estimated Expiration Related US Patent
Collagenase clostridium histolyticum Australia 2014228477 2033-03-15   Start Trial
Collagenase clostridium histolyticum Australia 2015206597 2033-03-15   Start Trial
Collagenase clostridium histolyticum Australia 2015261743 2033-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Merck
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.